Zimmer Biomet Holdings, Inc. ZBH recently announced that its Gel-One Cross-linked Hyaluronate, an advanced joint preservation treatment for knee osteoarthritis has received expanded safety claim from the U.S. Food and Drug Administration (FDA). As per this expanded FDA safety claim, this single-injection viscosupplement is safe for repeat treatments.
According to Zimmer Biomet, Gel-One Hyaluronate is the first low-volume viscosupplement available in a single-injection formulation for knee osteoarthritis patients, who have failed to respond adequately to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or simple analgesics, such as acetaminophen.
Hyaluronic acid (HA) products such as Gel-One Hyaluronate work as a supplement for the natural lubrication of the joint. With the expanded safety claim, physicians will now be able to safely utilize Zimmer Biomet’s knee joint solution in repeat treatment courses if required, to provide continued pain relief for patients. The decision comes as an encouraging development for Zimmer Biomet’ as it will help substantially expand the company’s portfolio of joint preservation treatments.
Post the merger with Biomet, the combined company has emerged as a leading innovator in the $45 billion musculoskeletal industry, ramping up the merged entity's position in the competitive niche. The merged entity is working to advance innovation and help create a more diversified and predictable revenue mix consistent with the comprehensive portfolio. Zimmer Biomet currently plans to invest more in research and development, and medical training and education, with an aim to develop and introduce cutting-edge musculoskeletal products and services to achieve improved patient outcomes.
The stock currently carries a Zacks Rank #2 (Buy).
Key Picks in the Sector
Some other well-ranked medical products stocks are GW Pharmaceuticals plc GWPH, ICU Medical, Inc. ICUI and INSYS Therapeutics, Inc. INSY. All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment